Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

NCT06613633 · clinicaltrials.gov ↗

COMPLETED

Status

4000

Enrollment

OTHER

Sponsor class

Conditions

Third-generation TKI
NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]